摘要
Two recent studies published in Nature focused on the clinical efficacy of the menin inhibitor revumenib(SNDX-5613)in KMT2A(histone-lysine N-methyltransferase 2A)-rearranged or NPM1(Nucleophosmin1)-mutant acute myeloid leukemia.1,2 These studies indicate that menin inhibition and its acquired resistance to long-term exposure to revuminib are key points for future treatment,emphasizing the role of menin as a challenging and promising target for the current treatment of leukemia.
